In this scenario, we examined IDO2 immunolabeling in 191 resected NSCLC cases, in order to better understand its expression in this cancer type and to determine its correlations with clinical-pathological parameters, other immunomodulatory molecules and patients' prognosis. Here, IDO2 is linked to cancer.